BR112013008523A2 - compostos de piridazina carboxamida substituídos - Google Patents
compostos de piridazina carboxamida substituídosInfo
- Publication number
- BR112013008523A2 BR112013008523A2 BR112013008523A BR112013008523A BR112013008523A2 BR 112013008523 A2 BR112013008523 A2 BR 112013008523A2 BR 112013008523 A BR112013008523 A BR 112013008523A BR 112013008523 A BR112013008523 A BR 112013008523A BR 112013008523 A2 BR112013008523 A2 BR 112013008523A2
- Authority
- BR
- Brazil
- Prior art keywords
- substituted carboxamide
- pyridazine compounds
- protein kinase
- carboxamide pyridazine
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Addiction (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39142310P | 2010-10-08 | 2010-10-08 | |
US61/391,423 | 2010-10-08 | ||
PCT/US2011/055428 WO2012048259A2 (en) | 2010-10-08 | 2011-10-07 | Substituted pyridazine carboxamide compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112013008523A2 true BR112013008523A2 (pt) | 2016-07-12 |
BR112013008523B1 BR112013008523B1 (pt) | 2021-12-07 |
Family
ID=45928473
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112013008523-1A BR112013008523B1 (pt) | 2010-10-08 | 2011-10-07 | Compostos de piridazina carboxamida substituídos e usos dos mesmos para tratar câncer, uma doença de proliferação, uma doença neurológica, uma doença psiquiátrica, obesidade, diabetes ou doença cardiovascular |
Country Status (12)
Country | Link |
---|---|
US (3) | US9126947B2 (pt) |
EP (1) | EP2625176B1 (pt) |
JP (2) | JP6023062B2 (pt) |
KR (1) | KR101886812B1 (pt) |
CN (1) | CN103298806B (pt) |
AU (1) | AU2011311814B2 (pt) |
BR (1) | BR112013008523B1 (pt) |
CA (1) | CA2813607C (pt) |
EA (1) | EA024809B1 (pt) |
ES (1) | ES2610226T3 (pt) |
PL (1) | PL2625176T3 (pt) |
WO (1) | WO2012048259A2 (pt) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011117286A1 (en) * | 2010-03-23 | 2011-09-29 | Basf Se | Pyridazine compounds for controlling invertebrate pests |
WO2012048259A2 (en) * | 2010-10-08 | 2012-04-12 | Xcovery Holding Company, Llc | Substituted pyridazine carboxamide compounds |
JP6013029B2 (ja) * | 2012-05-25 | 2016-10-25 | 千葉県 | 抗癌剤 |
RU2550346C2 (ru) * | 2013-09-26 | 2015-05-10 | Общество с ограниченной ответственностью "Отечественные Фармацевтические Технологии" ООО"ФармТех" | Новые химические соединения (варианты) и их применение для лечения онкологических заболеваний |
CN105085550B (zh) * | 2014-05-21 | 2017-05-24 | 海门慧聚药业有限公司 | 一类alk激酶抑制剂及其制备方法 |
RU2015110071A (ru) * | 2015-03-23 | 2016-10-10 | Общество с ограниченной ответственностью "Отечественные Фармацевтические Технологии" ООО "ФармТех" | Применение новых химических соединений (варианты) в качестве ингибиторов nuak1 киназы для лечения онкологических заболеваний |
TWI646094B (zh) * | 2016-06-01 | 2019-01-01 | 大陸商貝達藥業股份有限公司 | Crystal form of inhibitory protein kinase active compound and application thereof |
RU2631430C1 (ru) * | 2016-10-26 | 2017-09-22 | Общество С Ограниченной Ответственностью "Отечественные Фармацевтические Технологии" | НОВЫЙ СПОСОБ СИНТЕЗА ПРОИЗВОДНЫХ ТЕТРАГИДРОПИРАЗИНО[2,3-c]ПИРИДАЗИНА |
EP3778590A4 (en) * | 2018-04-09 | 2021-12-22 | ShanghaiTech University | COMPOUND TARGETING PROTEIN DEGRADATION, ANTITUMOR USE, INTERMEDIATE AND USE OF THE INTERMEDIATE |
WO2022031636A1 (en) | 2020-08-03 | 2022-02-10 | Teva Pharmaceuticals International Gmbh | Solid state forms of ensartinib and ensartinib salts |
WO2023016321A1 (zh) * | 2021-08-10 | 2023-02-16 | 贝达药业股份有限公司 | 恩沙替尼或其盐在治疗携带met 14外显子跳跃突变的疾病中的用途 |
CN116082110B (zh) * | 2023-01-09 | 2024-04-12 | 北京肿瘤医院(北京大学肿瘤医院) | 一种11c标记靶向间变性淋巴瘤激酶alk突变分子探针及应用 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4369172A (en) | 1981-12-18 | 1983-01-18 | Forest Laboratories Inc. | Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose |
EP0188040B1 (en) | 1985-01-11 | 1991-08-14 | Abbott Laboratories Limited | Slow release solid preparation |
JP2773959B2 (ja) | 1990-07-10 | 1998-07-09 | 信越化学工業株式会社 | 大腸内放出性固形製剤 |
UA73092C2 (uk) | 1998-07-17 | 2005-06-15 | Брістол-Майерс Сквібб Компані | Таблетка з ентеросолюбільним покриттям і спосіб її приготування |
EP1101490B1 (en) | 1998-07-28 | 2005-04-13 | Tanabe Seiyaku Co., Ltd. | Preparation capable of releasing drug at target site in intestine |
US6461631B1 (en) | 1999-11-16 | 2002-10-08 | Atrix Laboratories, Inc. | Biodegradable polymer composition |
US6800663B2 (en) | 2002-10-18 | 2004-10-05 | Alkermes Controlled Therapeutics Inc. Ii, | Crosslinked hydrogel copolymers |
OA13151A (en) | 2003-02-26 | 2006-12-13 | Sugen Inc | Aminoheteroaryl compounds as protein kinase inhibitors. |
PT1784396E (pt) | 2004-08-26 | 2011-01-27 | Pfizer | Compostos amino-heteroarílicos substituídos com pirazole como inibidores de proteína quinases |
JP2008510792A (ja) * | 2004-08-26 | 2008-04-10 | ファイザー・インク | タンパク質チロシンキナーゼ阻害剤としてのアミノヘテロアリール化合物 |
EP2120578B1 (en) | 2007-01-19 | 2014-11-19 | Xcovery, INC. | Kinase inhibitor compounds |
NZ590542A (en) * | 2008-06-19 | 2012-12-21 | Xcovery Holding Co Llc | Substituted pyridazine carboxamide compounds as kinase inhibitor compounds |
EA025030B1 (ru) * | 2010-10-08 | 2016-11-30 | Икскавери Холдинг Кампани, Ллс | Соединение {5-[(1r)-1-(2,6-дихлор-3-фторфенил)этокси]-6-аминопиридазин-3-ил}-n-(1-метил-6-оксо-1,6-дигидропиридин-3-ил)карбоксамид в качестве киназного ингибитора |
WO2012048259A2 (en) * | 2010-10-08 | 2012-04-12 | Xcovery Holding Company, Llc | Substituted pyridazine carboxamide compounds |
-
2011
- 2011-10-07 WO PCT/US2011/055428 patent/WO2012048259A2/en active Application Filing
- 2011-10-07 EA EA201390520A patent/EA024809B1/ru unknown
- 2011-10-07 JP JP2013532985A patent/JP6023062B2/ja active Active
- 2011-10-07 PL PL11831702T patent/PL2625176T3/pl unknown
- 2011-10-07 EP EP11831702.3A patent/EP2625176B1/en active Active
- 2011-10-07 KR KR1020137011872A patent/KR101886812B1/ko active IP Right Grant
- 2011-10-07 BR BR112013008523-1A patent/BR112013008523B1/pt active IP Right Grant
- 2011-10-07 ES ES11831702.3T patent/ES2610226T3/es active Active
- 2011-10-07 CN CN201180057513.0A patent/CN103298806B/zh active Active
- 2011-10-07 AU AU2011311814A patent/AU2011311814B2/en active Active
- 2011-10-07 US US13/877,783 patent/US9126947B2/en active Active
- 2011-10-07 CA CA2813607A patent/CA2813607C/en active Active
-
2015
- 2015-09-04 US US14/846,490 patent/US20160068493A1/en not_active Abandoned
-
2016
- 2016-06-23 JP JP2016124463A patent/JP6235078B2/ja active Active
-
2017
- 2017-05-03 US US15/585,961 patent/US20180016240A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EA201390520A1 (ru) | 2013-09-30 |
JP2016216475A (ja) | 2016-12-22 |
JP6235078B2 (ja) | 2017-11-22 |
US20180016240A1 (en) | 2018-01-18 |
AU2011311814A1 (en) | 2013-05-02 |
EP2625176A2 (en) | 2013-08-14 |
US20130190298A1 (en) | 2013-07-25 |
BR112013008523B1 (pt) | 2021-12-07 |
KR101886812B1 (ko) | 2018-08-08 |
US9126947B2 (en) | 2015-09-08 |
WO2012048259A3 (en) | 2012-06-28 |
EA024809B1 (ru) | 2016-10-31 |
ES2610226T3 (es) | 2017-04-26 |
CN103298806A (zh) | 2013-09-11 |
CN103298806B (zh) | 2015-03-18 |
JP2013539765A (ja) | 2013-10-28 |
PL2625176T3 (pl) | 2017-08-31 |
EP2625176A4 (en) | 2014-04-09 |
AU2011311814B2 (en) | 2016-12-22 |
US20160068493A1 (en) | 2016-03-10 |
KR20130141514A (ko) | 2013-12-26 |
WO2012048259A2 (en) | 2012-04-12 |
CA2813607C (en) | 2021-08-31 |
JP6023062B2 (ja) | 2016-11-09 |
EP2625176B1 (en) | 2016-08-17 |
CA2813607A1 (en) | 2012-04-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112013008523A2 (pt) | compostos de piridazina carboxamida substituídos | |
AU2018236800B2 (en) | DNA-PK inhibitors | |
TN2013000348A1 (en) | Compounds and compositions as trk inhibitors | |
MX343706B (es) | Derivados heterocíclicos novedosos. | |
MY174196A (en) | Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity | |
MX2010009207A (es) | Compuestos y composiciones heterociclicos como inhibidores de c-kit y pdgfr cinasa. | |
MX2009011951A (es) | Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr. | |
MY167245A (en) | Compounds and compositions as c-kit kinase inhibitors | |
TN2012000249A1 (en) | Pyrazine derivatives and their use in the treatment of neurological disorders | |
BRPI0811617A2 (pt) | derivados de primidina e composições como inibidores de c-kit e pdgfr quinase. | |
JO3366B1 (ar) | مثبطات بيرازوليل كوينوكزالين كاينيز | |
JO3002B1 (ar) | مركبات و تركيبات كمثبطات كيناز بروتين | |
EA024842B9 (ru) | Соединения в качестве модуляторов протеинкиназы pi3k | |
MX339937B (es) | Compuestos y composiciones como inhibidores de la quinasa c-kit. | |
MX2014002486A (es) | Compuestos y composiciones como inhibidores de cinasa pdgfr. | |
UY33597A (es) | Compuestos y composiciones como inhibidores de la trk | |
MX2013004307A (es) | Derivados de arilamida como bloqueadores de ttx-s. | |
WO2011014795A3 (en) | Compounds and compositions as syk kinase inhibitors | |
BRPI0914305B8 (pt) | compostos de piridazina carboxamida substituída como compostos inibidores da quinase, uso dos compostos e uso de uma composição compreendendo os compostos | |
NZ709153A (en) | Pyrimidinone derivatives having human neutrophil elastase inhibitory activity | |
MX366308B (es) | Derivados de amida como bloqueadores de ttx-s. | |
CA2878796C (en) | Derivatives of pyridinone as inhibitors for tissue transglutaminase | |
MX2009011952A (es) | Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr. | |
PH12016500978A1 (en) | Piperazine derivatives having multimodal activity against pain | |
MX360323B (es) | Derivados de pirrolopiridinona como bloqueadores de ttx-s. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B25F | Entry of change of name and/or headquarter and transfer of application, patent and certif. of addition of invention: change of name on requirement |
Owner name: XCOVERY HOLDING COMPANY LLC (US) Free format text: A FIM DE ATENDER A ALTERACAO DE NOME REQUERIDA ATRAVES DA PETICAO NO 870200054873 DE04/05/2020, E NECESSARIO ESCLARECER A DIVERGENCIA QUE HA ENTRE O ENDERECO APRESENTADO NAPETICAO SUPRA E O ATUAL ENDERECO DA REQUERENTE, CONFORME PETICAO 020130029909 DE 08/04/2013. |
|
B25G | Requested change of headquarter approved |
Owner name: XCOVERY HOLDINGS, INC. (US) |
|
B25D | Requested change of name of applicant approved |
Owner name: XCOVERY HOLDINGS, INC. (US) |
|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 07/10/2011, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO. |